AbbVie Announces U.S. FDA Granted Breakthrough Therapy Designati
ABBV: AbbVie Inc.
2022-01-04 08:15:00
AbbVie Announces U.S. FDA Granted Breakthrough Therapy Designation (BTD) to Telisotuzumab Vedotin (Teliso-V) for Previously Treated Non-Small Cell Lung Cancer
2022-01-04 08:15:00
AbbVie Announces U.S. FDA Granted Breakthrough Therapy Designation (BTD) to Telisotuzumab Vedotin (Teliso-V) for Previously Treated Non-Small Cell Lung Cancer